ACET Research | Milton Maxwell

ACET

Adicet Bio, Inc.

0.4650

-0.0300-6.06%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

71.26M

P/E (TTM)

Basic EPS (TTM)

-1.25

Dividend Yield

Recent Filings

8-K

Q4 loss $30.5M; prula-cel advances

3/12/26Mar 12, 2026

Adicet Bio reported Q4 2025 net loss of $30.5M, up slightly from $28.7M last year, with R&D at $25.0M amid rising CRO costs for autoimmune trials; full-year loss narrowed to $116.8M from $117.1M. Prula-cel enrollment surges in Phase 1 for lupus and RA, FDA-aligned for outpatient dosing. Cash at $158.5M funds ops into 2H/2027. ADI-212 filing set for 3Q/2026.

10-K

FY2025 results

3/12/26Mar 12, 2026

Adicet Bio posted FY2025 net loss of $116.8M on $122.1M opex, flat vs FY2024's $117.1M loss, burning $95.2M operating cash while ending with $158.5M cash runway into H2 2027. R&D held steady at $99.1M despite prula-cel autoimmune momentum—positive preliminary Phase 1 data from 7 LN/SLE patients (Oct 2025 cutoff), first SSc/RA doses, FDA outpatient alignment, Fast Track for LN/SLE/SSc, pivotal LN/SLE study eyed H2 2026. G&A fell 19% to $23.0M post-workforce cuts. No quarterly breakdowns disclosed in 10-K. Pipeline prioritized: ADI-212 IND Q3 2026; ADI-270 discontinued. Cash burn eased by $75M Oct offering. Dependence on prula-cel success risks clinical/regulatory delays.

8-K

Prula-cel enrollment doubles

1/7/26Jan 7, 2026

Adicet Bio doubled prula-cel Phase 1 enrollment to over 20 autoimmune patients by December 31, 2025, while securing FDA alignment for outpatient dosing in lupus nephritis and SLE trials. All seven cohorts now enroll actively. Plans target FDA meeting in Q2 2026 for pivotal design and ADI-212 filing in H1 2026. Cash runway extends into 2H/2027.

8-K

1-for-16 reverse split

12/29/25Dec 29, 2025

Adicet Bio filed for a 1-for-16 reverse stock split, effective December 30, 2025, slashing outstanding shares from 153.3 million to 9.6 million. Approved by stockholders on December 19 and the board same day, it targets Nasdaq minimum bid price compliance. Trading resumes split-adjusted under ACET. Cash replaces fractional shares.

8-K

Reverse split approved

12/19/25Dec 19, 2025

Adicet Bio stockholders overwhelmingly approved a reverse stock split on December 19, 2025, authorizing a ratio between 1-for-5 and 1-for-30 at board discretion. With 111 million votes for versus just 2.8 million against, the move sets up share consolidation. Board picks the exact ratio soon.

About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

CEO

Mr. Chen Schor BA, CPA, M.B.A.

IPO

1/26/2018

Website

https://www.adicetbio.com

Employees

152

Sector

Healthcare

Industry

Biotechnology